MenABCWY Meningococcal Vaccine Description
Pfizer’s pentavalent meningococcal vaccine candidate combines its two approved meningococcal vaccines, Nimenrix™ (meningococcal group A, C, W-135, and Y conjugate vaccine) and Trumenba® (meningococcal group B vaccine).
Approvals of Nimenrix™ and Trumenba® vary by country.
MenABCWY Meningococcal Vaccine Indication
MenABCWY Meningococcal vaccine candidate is indicated to prevent meningococcal disease.
Meningococcal disease is an uncommon but serious disease that can attack without warning and lead to meningitis and serious blood infections.
The majority of invasive meningococcal disease cases worldwide can be attributed to five Neisseria meningitidis groups (A, B, C, W, and Y).
Together, these meningococcal groups account for 96% of all invasive meningococcal disease (IMD), with group B accounting for the majority of disease in adolescents and young adults in the U.S. and Europe.
MenABCWY Meningococcal Vaccine News
June 22, 2020 - Initiation of the Phase 3 trial is based on positive results from a proof-of-concept study in 543 adolescents and young adults. Detailed results from the proof-of-concept study have been submitted for presentation at ID Week 2020.
MenABCWY Meningococcal Vaccine Clinical Trials
Clinical Trial NCT04440163: MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
This phase 3 study of the pentavalent meningococcal vaccine candidate, MenABCWY, in adolescents and young adults will assess the safety, tolerability, and immunogenicity of the MenABCWY vaccine candidate compared to licensed meningococcal vaccines, with the goal of determining immunologic noninferiority.
This Phase 3 trial will enroll approximately 2,413 adolescents and young adults (10 through 25 years of age) from the United States and Europe.